ClaripulseClaripulse
MAUDE LookupResourcesBlog
LoginGet Early Access
ClaripulseClaripulse

Product

MAUDE LookupDashboard

Guides

FDA MAUDE DatabasePost-Market SurveillanceSignal Detection

Learn

BlogResourcesWhy Claripulse?

Legal

Privacy PolicyTerms of Service

This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified — do not attempt re-identification. © 2026 Claripulse.

Back to Coronary Intervention
MAUDE LookupCoronary InterventionSYNERGY

SYNERGY Adverse Events: FDA MAUDE Data

BOSTON SCIENTIFIC CORPORATION · Coronary Drug-Eluting Stent · First cleared Oct 2015

Total Reports

5,991

Reports (30d)

32

Active Signals

1

Open Recalls

0

Monthly Report Volume
Event Type Breakdown

What the reports describe · Claripulse analysis

Most commonly reported problems

1

Stent Flare Off Balloon Before Use

synergy, lesion located, shaft, completed, synergy drug

34

reports

2

Patient Death Following Stent Placement

synergy, cardiac, reference, lesion located, died

17

reports

3

Proximal Edge Dissection Post-Deployment

dissection, dissection occurred, located, synergy, lesion located

16

reports

4

In-Hospital Stent Thrombosis After Implant

thrombosis, article, patients, myocardial infarction, death

12

reports

5

Stent Crossing Failure in Tortuous Anatomy

located, procedure completed, stenosed target, encountered, completed

5

reports

Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.

Detection

Active safety signals

Disproportionate reportinghigh

Evidence

Related research

Architecting Synergy: Knowledge Graphs for Representing Complex, Multi-Domain Patient Information.

Keshavjee K. · 2026

Antibiotic Adjuvant Potential of Selected Essential Oil Components Against Respiratory Pathogens: From Planktonic Synergy to Early-Stage Biofilm Inhibition.

Balázs VL, et al. · 2026

Molecular design of high dipole moment polyacrylates: achieving anti-plasticization and high moisture permeability through interfacial polarization synergy.

Ma J, et al. · 2026

Strength-Ductility Synergy and Microscopic Mechanism of CNTs-Reinforced Mg-Al Composites Fabricated Through Vacuum Powder Metallurgy Coupled with Hot Extrusion-Rolling.

Ma S, et al. · 2026

Synergy of Coronary Revascularization and Optimal Drug Therapy in Patients With Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction.

Kadyrov BA. · 2026

Citations indexed from PubMed.

Keep exploring

Related devices in Coronary

Perclose ProGlide

ABBOTT VASCULAR INC. · 24,504 reports

→

Perclose ProStyle

ABBOTT VASCULAR INC. · 19,336 reports

→

PERCLOSE

ABBOTT VASCULAR INC. · 9,890 reports

→

Angio-Seal

TERUMO MEDICAL CORPORATION · 6,417 reports

→

Resolute Onyx

MEDTRONIC, INC. · 4,467 reports

→

Promus PREMIER

BOSTON SCIENTIFIC CORPORATION · 2,717 reports

→

Want automated safety signal detection?

Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 1 active signal detected right now.

Get Early Access

Understanding this data

What FDA MAUDE data does and does not tell you

How these reports are filed, why raw counts mislead, and the limits to know before drawing conclusions.

→

How a safety signal is detected

What the "Active Signals" count above means and the methods that separate a real signal from noise.

→
Disclaimer: This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified. Do not attempt re-identification. Report counts may differ from the FDA's MAUDE search due to processing cadence and deduplication. Data is updated weekly.